Fentanyl - The World's First Kit and Patent Submission to IDenta Corp.
JERUSALEM, Israel, June 19, 2017 /PRNewswire/ --
IDenta Corp. (OTC PINK: IDTA), a world leader in the development of field kits, has developed a patent for the identification of Fentanyl. Fentanyl is a very dangerous drug that causes the death of people every day around the globe. There is an extensive demand for the new kit by some of the most important and leading police forces which has an affect worldwide, with countries looking for an urgent solution like IDenta's unique patent to save lives.
About IDenta Corp.
Since 2002, IDenta Corporation and its subsidiary IDenta Ltd are recognized as a worldwide leader in the development of proprietary on-site Drug, Precursor of Drug and Explosive detection kits. IDenta develops, manufactures and distributes revolutionary products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.
Disclaimer
Certain statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
Contact
Amichai Glattstein, COO
T: +972-2587-2220
E: [email protected]
SOURCE Identa Corp
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article